Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elafibranor - Genfit

Drug Profile

Elafibranor - Genfit

Alternative Names: GFT505

Latest Information Update: 08 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genfit
  • Class Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Antihyperlipidaemics; Hepatoprotectants; Small molecules
  • Mechanism of Action Antioxidants; Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary biliary cirrhosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-alcoholic steatohepatitis
  • Phase II Non-alcoholic fatty liver disease; Primary biliary cirrhosis
  • Phase I Liver disorders
  • No development reported Hepatic fibrosis; Lipid metabolism disorders; Type 2 diabetes mellitus

Most Recent Events

  • 30 Sep 2019 Efficacy data from a phase II trial in primary biliary cirrhosis released by Genfit
  • 30 Sep 2019 Genfit plans a phase III trial for Primary biliary cirrhosis in Q1 2020
  • 23 Sep 2019 Genfit initiates a phase I trial in healthy volunteers in France (PO, Tablet) (NCT03985969)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top